The overexpression of RUNX2 has been reported in several tumors, including T-cell lymphoma, acute myeloid leukemia [43,44], and, recently, T-cell acute lymphoblastic leukemia (T-ALL) [62]. Here, RUNX2 is linked to T-cell non-Hodgkin lymphoma.